Drug Trial Radar · NCT05199753
Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Mar 16, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- LaNova Australia Pty LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase I/II, open-label, multi-centre, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumour activity of LM-108 as a single agent or in combination with an anti-PD-1 mAb in subjects with solid tumours.
Conditions
- Advanced Solid Tumor
Interventions
LM-108Drug
Administered intravenously
An Anti-PD-1 AntibodyDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: 126 weeks
- Incidence of dose-limiting toxicity (DLT)Time frame: 126 weeks
- Incidence of serious adverse event (SAE)Time frame: 126 weeks
- Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.Time frame: 126 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Blacktown Hospital
Sydney, New South Wales, Australia
Sunshine Coast University Private Hospital
Birtinya, Queensland, Australia
ICON Cancer Centre
South Brisbane, Queensland, Australia
Cabrini Health Limited
Malvern, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
One Clinical Research Pty Ltd.
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.